An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer

NCT06436885 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

39

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Iruplinalkib tablets

Sponsor

Henan Cancer Hospital